SuperworthUnited Therapeutics EPS UTHR
Diluted earnings per share by quarter and over the last twelve months, from 2009.
- Last 12 months, to Jun 30, 2026
- $27.95
- Latest quarter, Q2 FY26
- $7.27
- +13% on a year earlier
- Fiscal year 2025
- $27.90
- +13% on the year before
United Therapeutics' earnings per share was $27.95 over the twelve months to Jun 30, 2026, up 9% on a year earlier.
In its latest quarter, Q2 FY26, it was $7.27, up 13% on the same quarter a year before.
Over the five fiscal years to FY2025 it grew 19% a year on average.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $27.90 | +13% |
| FY2024 | $24.62 | +24% |
| FY2023 | $19.82 | +32% |
| FY2022 | $15.02 | +50% |
| FY2021 | $10.02 | −13% |
| FY2020 | $11.56 | n/a |
| FY2019 | −$2.45 | −118% |
| FY2018 | $13.45 | +44% |
| FY2017 | $9.34 | −38% |
| FY2016 | $15.16 | +18% |
| FY2015 | $12.89 | +109% |
| FY2014 | $6.17 | +88% |
| FY2013 | $3.28 | −42% |
| FY2012 | $5.69 | +58% |
| FY2011 | $3.59 | +104% |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $7.27 | +13% | $27.95 | |
| Q1 FY26 | $5.82 | −12% | $27.09 | |
| Q4 FY25 | $7.70 | +24% | $27.90 | |
| Q3 FY25 | $7.16 | +12% | $26.41 | |
| Q2 FY25 | $6.41 | +10% | $25.64 | |
| Q1 FY25 | $6.63 | +7% | $25.08 | |
| Q4 FY24 | $6.21 | +43% | $24.62 | |
| Q3 FY24 | $6.39 | +19% | $22.75 | |
| Q2 FY24 | $5.85 | +12% | $21.74 | |
| Q1 FY24 | $6.17 | +27% | $21.13 | |
| Q4 FY23 | $4.34 | +63% | $19.82 | |
| Q3 FY23 | $5.38 | +10% | $18.15 |
Against its peers
Companies in Biotechnology nearest United Therapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| UTHRUnited Therapeutics | $27.95 | +9% a year |
| INCYIncyte | $7.85 | +78% a year |
| ALNYAlnylam Pharmaceuticals | $5.93 | |
| EXELExelixis | $3.18 | +53% a year |
| ONCBeOne Medicines | $0.43 | |
| NBIXNeurocrine Biosciences | $6.82 | +102% a year |
| HALOHalozyme Therapeutics | $3.35 | −23% a year |
| TECHBIO-TECHNE | $1.15 | +150% a year |
| RGENRepligen | $0.73 | |
| KRYSKrystal Biotech | $7.98 | +62% a year |
| REGNRegeneron Pharmaceuticals | $40.44 | +2% a year |
| Peer median | $4.64 |
Where United Therapeutics ranks
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on United Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.